GlassScriptPhysician profile
Erik K Muraskas
NPI 1609840750
$325.54
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $41.43 · 2021: $18.46 · 2022: $40.23.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $95.56 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.68 | 2019 | |
| Allergan, INC. | $34.69 | 2019-2020 | |
| Pfizer INC. | $31.54 | 2019-2020 | |
| Duchesnay USA Incorporated | $30.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.12 | 2019 | |
| Agile Therapeutics, INC. | $18.46 | 2021 | |
| Alkermes, INC. | $18.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.12 | 2019 | |
| Dysis Medical, INC. | $13.87 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Muraskas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.